Time to give Celsion Corp. (NASDAQ:CLSN) a wide berth?


Celsion Corporation (NASDAQ:CLSN)’s shares have moved between a high of $-85.76% and a low of $18.75% over the previous 12 months.

For the last 50 days, the equity has risen to a peak price of $-42.54% and hit a bottom of $18.75%.

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

Recently, Celsion Corporation (NASDAQ:CLSN) announced that on moving volumes, the 20-Day Simple Moving Average of stock is $-10.47%, 50-Day SMA is $-21.30% and 200-Day SMA is $-66.52%.

The equity is now moved -33.01% for the year. Over the previous six months it has recorded movement of -70.06%, compared with a movement of -3.98% for the quarter, -17.42% for the month and 5.87% for the week.

The average volume, which is a measurement of three-months average, is 551.24K. Relative volume hand is 5.73. In total, Celsion Corporation has 3.95M shares due, with 3.87M of them being free float shares.

Institutional investors own 6.60% of Celsion Corporation’s equity, while insiders own 0.30% of the stock. In the last few months, the equity has seen -23.71% institutional investor transactions, as against – insider transactions.

How have the shareholders seen their investment in the equity change? Celsion Corporation’s┬áreturn on equity for the previous 12 months is -215.40% and return on investments for a same period calculates to -229.70%. The firm posted return on assets of -60.30% for the same 12 months period.

Does Celsion Corporation can keep its doors open at least over the interim? The firm’s current ratio at the close of the recent quarter was 0.50, while quick ratio for the equivalent period was 0.50.

For the debt matters, the firm’s Long Term Debt/Equity for the recent quarter was 0.00 and Total Debt/Equity for the equivalent period was 0.25.

Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided an update on its OVATION Study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company’s DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced (stage III/IV) ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. GEN-1 is an IL-12 DNA plasmid vector formulated as a nanoparticle in a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally at the tumor site.